Vanguard Asset Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.5M Buy
46,177
+1,207
+3% +$215K 0.01% 710
2026
Q1
$7.76M Buy
+44,970
New +$8.34M 0.01% 735

Other funds holding CRL

Vanguard Asset Management's CRL Position: Q2 2026 in Review

Vanguard Asset Management increased its Charles River Laboratories (CRL) stake by 2.7% in Q2 2026, buying an estimated $215K and bringing the position to 46,177 shares worth $10.5M. The position accounts for 0.01% of the portfolio, ranked #710.

Vanguard Asset Management first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 531 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Vanguard Asset Management held 46,177 shares of Charles River Laboratories worth $10.5M as of Q2 2026.
  • Vanguard Asset Management bought 1,207 Charles River Laboratories shares in Q2 2026, an estimated $215K.
  • Charles River Laboratories made up 0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #710 holding.
  • Vanguard Asset Management first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • 531 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.